Banque Pictet & Cie Sa Mirati Therapeutics, Inc. Transaction History

Banque Pictet & Cie Sa

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$36.54 - $54.26 $181,274 - $269,183	-4,961 Reduced 31.2%	10,941 $406,000
Q4 2022 Feb 06, 2023	SELL	$41.27 - $98.62 $207,092 - $494,875	-5,018 Reduced 23.99%	15,902 $0
Q3 2022 Nov 10, 2022	SELL	$59.5 - $86.7 $392,521 - $571,959	-6,597 Reduced 23.97%	20,920 $1.46 Billion
Q2 2022 Aug 08, 2022	BUY	$39.16 - $88.71 $553,800 - $1.25 Million	14,142 Added 105.73%	27,517 $1.85 Million
Q1 2022 May 04, 2022	BUY	$75.82 - $150.97 $39,274 - $78,202	518 Added 4.03%	13,375 $1.1 Million

Q4 2021 Feb 02, 2022	BUY	$132.01 - $190.29 $1.7 Million - $2.45 Million	12,857 New	12,857 $1.89 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.